Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.33-
QQQ
716.250.03%
BTC/USD
78223.130.0138%
DIA
535.550.09%
GLD
409.230.08%
TLT
82.940.07%

West Pharmaceutical Services Inc

WSTNYSE
Trade with Public
Trade with Public
$337.47
-8.62-2.49%
At close: Aug 28, 5:00 PM EST
$337.47
N/A
After Hours: Aug 28, 4:02 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipDividendsCompareOptionsStock Report

West Pharmaceutical Servs Analyst Price Targets

Wall Street analyst price targets and consensus rating for West Pharmaceutical Servs (WST).

Price Target Range — 11 Quarters

Analyst Consensus — 12 Analysts

12Buy
Consensus RatingBuy# Analysts12Avg. Consensus PT$393Upside to Avg. PT+16.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 3, 2026CitigroupJoanne WuenschPT RaiseBuy$400→$412
Jul 27, 2026Evercore ISI GroupDaniel MarkowitzPT RaiseOutperform$410→$425
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412

Citigroup analyst Joanne Wuensch maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $400 to $412.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425

Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $410 to $425.
Benzinga Newsdesk

PRO
BNP Paribas Initiates Coverage On West Pharmaceutical Servs with Outperform Rating, Announces Price Target of $447

BNP Paribas analyst Curtis Moiles initiates coverage on West Pharmaceutical Servs (NYSE:WST) with a Outperform rating and announces Price Target of $447.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $365

Morgan Stanley analyst Kallum Titchmarsh maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and raises the price target from $325 to $365.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $410

Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $390 to $410.
Benzinga Newsdesk

PRO
Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $390

Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $350 to $390.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved